Letter of Support for CGM Coverage
October 9, 2019 | We wrote a letter to the Minister of Health and Social Services of the province of Quebec supporting coverage of continuous glucose monitors (CGMs) in the public health and prescription drug insurance plan for Quebec.
Diabetes Advocacy Alliance Letter to the National Clinical Care Commission
October 8, 2019 | We joined the DAA coalition in a letter to the NCCC highlighting considerations for them to consider and provide recommendations on the coordination and leveraging of federal programs related to complex metabolic or autoimmune diseases that result from insulin-related issues such as diabetes.
Cognitive Specialty Coalition Letter to Cigna
October 2, 2019 | We joined this coalition to send a letter to Cigna's Chief Medical Officer in regards to Cigna's new policy on Evalutation and Management (E/M) which will result in Cigna discontinuing payment for consultation services as of October 19, 2019.
Comments on CMS 2020 Physician Fee Schedule
September 27, 2019 | We submitted comments to CMS Adminsitrator Seema Verma on the proposed revisions to the payment policies under the Medicare Physician Fee Schedule for 2020.
Cognitive Care Alliance Letter on E/M Services
September 23, 2019 | We joined the Cognitive Care Alliance in a letter to CMS Administrator Seema Verma to provide comments about the agency's proposals related to the payment for evaluation and management (E/M) services included in the CY 2020 Physician Fee Schedule proposed rule.
Coalition Letter on Special Diabetes Reauthorization
September 17, 2019 | We joined a coalition of organizations urging House and Senate leaders to renew the Special Diabetes Program before September 30 when it is set to expire.
Coalition Fetal Tissue Research Letter
September 16, 2019 | The Endocrine Society joined a coalition of organizations calling on the NIH to eliminate or modify procedures described in new NIH policies on research using fetal tissue to protect the scientific peer-review process, ease compliance, and clarify the new requirements.
Representing the Endocrine Society, our members strive to influence public policy related to research and clinical endocrinology issues by testifying before the United States Congress, Federal agencies, and other legislative and deliberative bodies.